D-1174-2023 Class I Ongoing
FDA drug recall D-1174-2023 was initiated by Novartis Pharmaceuticals Corp. on Sep 8, 2023 and is designated Class I. Reason for recall: Crystallization: bottles of Sandimmune Oral Solution were determined to contain crystals. The recall status is ongoing. Affected quantity: 1272 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Sep 27, 2023
- Initiation Date
- Sep 8, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 1272 bottles
Product description
SANDIMMUNE Oral Solution (cyclosporine oral solution, USP) 100 mg/mL, 50 mL bottle, Rx Only, Manufactured by: DELPHARM Huningue S.A.S., Huningue, France, Distributed by: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936, NDC 0078-0110-22.
Reason for recall
Crystallization: bottles of Sandimmune Oral Solution were determined to contain crystals.
Distribution pattern
Nationwide in the USA
Code information
FX001691, Exp. 12/31/2025
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1174-2023
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026